Alport

Edit

Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome

Pharmiweb 09 Dec 2025

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome.

Edit

Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

Caledonian Record 04 Dec 2025

Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026 ....

Edit

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

Caledonian Record 04 Dec 2025

BERLIN--(BUSINESS WIRE)--Dec 4, 2025-- ....

Edit

MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome (Bayer AG)

Public Technologies 04 Dec 2025

"We are collaborating closely with the patient organization community to gain a deeper understanding of the real challenges faced by people living with Alport Syndrome ... Both men and women are affected by Alport Syndrome ... About Alport Syndrome.

Edit

Alport Syndrome Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and ...

GetNews 19 Nov 2025

Company name Inactive Products Alport Syndrome Key Companies Alport Syndrome Key Products Alport Syndrome- Unmet Needs Alport Syndrome- Market Drivers and Barriers Alport Syndrome- Future Perspectives and Conclusion Alport Syndrome Analyst Views 22.

Edit

Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome at the American ...

The Daily Times 11 Nov 2025

... Alport syndrome were presented in a High-Impact Clinical .

Edit

Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome at the American Society of Nephrology Kidney Week

PR Newswire 10 Nov 2025

Alport syndrome is a rare genetic kidney disease resulting from mutations in collagen type IV genes that can lead to progressive loss of kidney function and end-stage kidney disease.

Edit

Alport Syndrome Clinical Landscape, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Enyo ...

GetNews 03 Nov 2025

"Alport Syndrome Clinical Landscape" ... Alport Syndrome Overview . ... Alport Syndrome Pipeline Analysis ... Download Alport Syndrome Sample report to know in detail about the Alport Syndrome treatment market @ Alport Syndrome Therapeutic Assessment.

Edit

Alport Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Pfizer, Theralase Technologies, ...

GetNews 28 Oct 2025

"Alport Syndrome Clinical Trials". DelveInsight’s, “Alport Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Alport Syndrome pipeline landscape ... Alport Syndrome Overview ..

Edit

IS THERE A CONTRADICTION BETWEEN THE GAMBIA PORTS AUTHORITY AND ALPORT?

Foroyaa 24 Oct 2025

The rumours are rife ... Its assets should be properly preserved ... ....

Edit

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

The Facts 22 Oct 2025

Chuo-ku, Tokyo; "Renalys") is pleased to announce the ...

Edit

Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)

PR Newswire 17 Oct 2025

TOKYO, Oct. 17, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters ... RE-021) — one investigating the use of sparsentan in focal segmental glomerulosclerosis (FSGS) and the other in Alport syndrome (AS) in Japan ... brand name ... About Alport Syndrome (AS).

Edit

Alport syndrome Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders – DelveInsight | Featuring ...

GetNews 25 Sep 2025

"Alport syndrome Pipeline 2025". DelveInsight’s, “Alport Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Alport Syndrome pipeline landscape ... Alport syndrome Overview ..

Podcasts:

Latest News for: alport

Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome

Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome (Bayer AG)

Alport Syndrome Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and ...

Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome at the American ...

Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome at the American Society of Nephrology Kidney Week

Alport Syndrome Clinical Landscape, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Enyo ...

Alport Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Pfizer, Theralase Technologies, ...

IS THERE A CONTRADICTION BETWEEN THE GAMBIA PORTS AUTHORITY AND ALPORT?

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)

Alport syndrome Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders – DelveInsight | Featuring ...

Article Search

EXPLORE WN.com